Cognition Therapeutics, Inc. announced it has received an anonymous philanthropic donation to substantially fund an Expanded Access Program (EAP) for zervimesine (CT1812) in people with dementia with Lewy bodies (DLB). The donation came from the family of a DLB patient who participated in the Phase 2 SHIMMER study.
This open-label EAP will provide eligible participants with 100 mg of oral zervimesine daily for approximately one year. Dr. James E. Galvin of the University of Miami will serve as the lead investigator for the multi-center program, with Banner Sun Health Research Institute in Arizona being the first of eight sites activated.
Initially, the EAP will accommodate approximately 30 individuals, with potential for more patients as funding and drug supply allow. This program offers access to zervimesine for patients with a significant unmet medical need and reflects external confidence in the drug's potential.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.